



FOR IMMEDIATE RELEASE

## Bonti to Present at Two Prestigious Healthcare Conferences

*Fauad Hasan, CEO and Co-founder, to Spotlight the Company in San Francisco*

**NEWPORT BEACH, CA, USA – January 5, 2018** – Bonti, a privately-held, clinical-stage biotechnology company, today announced that Fauad Hasan, CEO and co-founder, will present at the following in San Francisco the same week as the 36<sup>th</sup> Annual J.P. Morgan Healthcare Conference:

- The Neuroscience Innovation Forum on Sunday, January 7<sup>th</sup> at 1:50 PM (PT)
- The 5<sup>th</sup> Annual Dermatology Summit on Sunday, January 7<sup>th</sup> at 3:15 PM (PT)

Mr. Hasan will present highlights of the Company's technology and strategy during his presentations. He will focus on Bonti's lead product candidate, EB-001, which is a novel *botulinum* neurotoxin with a unique target profile, characterized by fast onset of action and short duration of effect. The clinical safety and efficacy of EB-001 is being investigated in Phase 2 clinical trials, including in the Company's LANTERN-1 pain study, as part of its development for therapeutic and aesthetic indications with significant addressable market opportunities.

"We are honored to be participating in the Neuroscience Innovation Forum and in The Dermatology Summit this year," said Fauad Hasan, CEO and co-founder. "We look forward to sharing details surrounding our compelling opportunity with the two meetings' attendees in San Francisco. We will discuss our progress and success in 2017, a year filled with noteworthy achievements, and outline how we plan to continue making strides in advancing the pipeline for our lead candidate, EB-001, in the coming year."

### **About EB-001**

Bonti's lead product candidate, EB-001, is an investigational *botulinum* neurotoxin serotype E (BoNT/E). EB-001 has a mechanism of action similar to the marketed *botulinum* neurotoxin serotype A (BoNT/A) products though it has a differentiated clinical profile. EB-001 has a fast onset of action (within 24 hours) and a short duration of effect (about 3 – 4 weeks). Currently marketed BoNT/A products have an onset of action around 3 – 7 days and a duration of effect around 3 – 4 months. The unique target clinical profile of EB-001 may be well suited for a vast range of aesthetic and therapeutic uses, including for the treatment of post-surgical and non-surgical musculoskeletal pain, with currently unmet needs.

## **About Bonti**

Bonti, based in Newport Beach, California, is a rapidly emerging biotechnology company founded by world class neurotoxin experts with proven prior success at Allergan. This team, with deep neurotoxin, aesthetic and pain expertise, is uniquely qualified to develop treatment paradigms driven by a novel neurotoxin platform designed to become an innovative leader in both aesthetic and therapeutic markets. By turning the science of neurotoxins into beneficial patient and healthcare provider solutions, Bonti seeks to improve lives by successfully addressing key unmet needs in markets with significant addressable opportunities.

For more information, please visit <http://bonti.com>.

### Contact

Orlando Rodrigues

Media Relations

[orlando@bonti.com](mailto:orlando@bonti.com)

760.212.5727